EditorialEditorial

Inconsistent radiotherapy effects between primary tumors and axillary lymph nodes

Zhao Bi, Pengfei Qiu, Zhaopeng Zhang and Yongsheng Wang
Cancer Biology & Medicine December 2022, 19 (12) 1617-1621; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0590

References

  1. 1.↵
    2. Greenup RA,
    3. Peppercorn J,
    4. Worni M,
    5. Hwang ES.
    Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. Ann Surg Oncol. 2014; 21: 1512–4.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Anderson SJ,
    3. Wapnir I,
    4. Dignam JJ,
    5. Fisher B,
    6. Mamounas EP,
    7. Jeong JH, et al.
    Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009; 27: 2466–73.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Houssami N,
    3. Macaskill P,
    4. Marinovich ML,
    5. Morrow M.
    The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014; 21: 717–30.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Bartelink H,
    3. Horiot JC,
    4. Poortmans PM,
    5. Struikmans H,
    6. Van den Bogaert W,
    7. Fourquet A, et al.
    Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25: 3259–65.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Jones HA,
    3. Antonini N,
    4. Hart AA,
    5. Peterse JL,
    6. Horiot JC,
    7. Collin F, et al.
    Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009; 27: 4939–47.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Krag DN,
    3. Anderson SJ,
    4. Julian TB,
    5. Brown AM,
    6. Harlow SP,
    7. Costantino JP, et al.
    Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010; 11: 927–33.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Giuliano AE,
    3. McCall L,
    4. Beitsch P,
    5. Whitworth PW,
    6. Blumencranz P,
    7. Leitch AM, et al.
    Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010; 252: 426–32.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    2. Donker M,
    3. van Tienhoven G,
    4. Straver ME,
    5. Meijnen P,
    6. van de Velde CJ,
    7. Mansel RE, et al.
    Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomized, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15: 1303–10.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Sávolt Á,
    3. Péley G,
    4. Polgár C,
    5. Udvarhelyi N,
    6. Rubovszky G,
    7. Kovács E, et al.
    Eight-year follow up result of the OTOASOR trial: The Optimal Treatment of the Axilla-Surgery or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017; 43: 672–9.
    OpenUrl
  10. 10.↵
    2. Li JJ,
    3. Cheng JY,
    4. Liu GY,
    5. Hou Y,
    6. Di G,
    7. Yang B, et al.
    Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial. Cancer Biol Med. 2022; 19: 1100–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Robert W,
    3. Benjamin O,
    4. Harold J,
    5. William J,
    6. Meena S,
    7. Jame A, et al.
    Breast cancer, Version 1.2022 NCCN guidelines. National Comprehensive Cancer Network. Available from: http://www.NCCN.org.
  12. 12.↵
    2. Rantanen V,
    3. Grénman S,
    4. Kulmala J,
    5. Jaakkola M,
    6. Lakkala T,
    7. Sajantila A, et al.
    Characterization and radiosensitivity of UT-EC-2A and UT-EC-2B, two new highly radiosensitive endometrial cancer cell lines derived from a primary and metastatic tumor of the same patient. Gynecol Oncol. 1995; 56: 53–62.
    OpenUrlPubMed
  13. 13.↵
    2. Huerta S,
    3. Heinzerling JH,
    4. Anguiano-Hernandez YM,
    5. Huerta-Yepez S,
    6. Lin J,
    7. Chen D, et al.
    Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res. 2007; 142: 184–94.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Hara T,
    3. Iwadate M,
    4. Tachibana K,
    5. Waguri S,
    6. Takenoshita S,
    7. Hamada N.
    Metastasis of breast cancer cells to the bone, lung, and lymph nodes promotes resistance to ionizing radiation. Strahlenther Onkol. 2017; 193: 848–55.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Gottschalk A,
    3. Sharma S,
    4. Ford J,
    5. Durieux ME,
    6. Tiouririne M.
    The role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010; 110: 1636–43.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Zhou L,
    3. Li Y,
    4. Li X,
    5. Chen G,
    6. Liang H,
    7. Wu Y, et al.
    Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J Immunol. 2016; 196: 3460–9.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Ma W,
    3. Wang K,
    4. Du J,
    5. Luan J,
    6. Lou G.
    Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer. Mol Med Rep. 2015; 11: 2999–3008.
    OpenUrl
  18. 18.↵
    2. Bakos O,
    3. Lawson C,
    4. Rouleau S,
    5. Tai LH.
    Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018; 6: 86.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    2. Li C,
    3. Jiang P,
    4. Wei S,
    5. Xu X,
    6. Wang J.
    Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020; 19: 116.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. van der Veeken J,
    3. Gonzalez AJ,
    4. Cho H,
    5. Arvey A,
    6. Hemmers S,
    7. Leslie CS, et al.
    Memory of inflammation in regulatory T cells. Cell. 2016; 166: 977–90.
    OpenUrlPubMed
  21. 21.↵
    2. Li MO,
    3. Rudensky AY.
    T cell receptor signaling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016; 16: 220–33.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Xu P,
    3. Zhang P,
    4. Sun Z,
    5. Wang Y,
    6. Chen J,
    7. Miao C.
    Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway. Cancer Immunol Immunother. 2015; 64: 1383–92.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section